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Case Report
Abstract
New-onset diabetes after transplantation (NODAT) is an important metabolic complication of transplantation because 
of its associated morbidity and mortality. Risk factors for NODAT include those known to cause diabetes mellitus in 
non-transplant patients as well as transplant-specific factors. This study was aimed at illustrating the presentation 
and management of NODAT in three kidney transplant recipients in our center and reviewing the literature. To our 
knowledge, this is the first report from Nigeria. Two of the patients were males of ages 60 and 36 years, respectively, 
while the third was a female aged 25 years. They were all receiving prednisolone, two were on tacrolimus, and one 
was on cyclosporine as part of their immunosuppressive regimens. They developed NODAT at varying times post 
transplant, ranging from 3 months to 6 years. Two patients were managed with oral hypoglycemic agents and one with 
insulin. One patient died of hemorrhagic stroke. We conclude that NODAT occurred in our kidney transplant recipients 
and recommend that physicians should have a high index of suspicion in order to make an early diagnosis and institute 
appropriate management to reduce morbidity and mortality.
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Introduction
Patient and allograft survivals after kidney transplants have 
improved over the last half century, leaving aside other 
complications such as malignancies, opportunistic infections, 
cardiovascular disease, and metabolic complications as 
important barriers to disease-free survival.[1]
New-onset diabetes after transplantation (NODAT), also 
called post-transplant diabetes mellitus, is an important 
complication because of its associated morbidity and 
mortality.[2]
Many risk factors have been identified for the development 
of NODAT such as immunosuppressive medications, 
family history of diabetes, and black race.[3] Unfortunately, 
there is paucity of data on NODAT from indigenous black 
African populations. We present three illustrative case 
series seen in our center and review the literature.
Case Summaries
Case 1
A 60-year-old civil servant who had living related kidney 
transplant 6 years prior to presentation. The donor was 
his son. He was hepatitis C positive with no evidence 
of active liver disease prior to kidney transplantation; 
liver enzymes were normal, no detectable viremia by 
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quantitative polymerase chain reaction (PCR), and liver 
histology was normal. His tissue typing was; HLA CLASS I 
A9 (23), A19 (29), B78, B70, BW6, CW2, CLASS II DR3, 
DR6 (13), DR51, DR52, DQ1, DQ4. His post-transplant 
immunosuppressive medications include prednisolone 
started on 20 mg and tapered to 5 mg daily starting from 
third month post transplant, tacrolimus 2 mg twice daily, 
and sirolimus 2 mg daily. His primary renal disease was 
hypertensive nephropathy. He had no family history of 
diabetes mellitus. He had no history of cigarette smoking 
or alcohol ingestion. He had no immediate post-transplant 
complications and maintained normal graft function 
until the current presentation. He presented 6 years after 
transplant with an acute diarrheal illness of 2 days’ duration. 
The diarrhea was watery, non-bloody, and non-mucoid with 
a frequency of 5–6 times daily but no associated fever. He 
had no history of  osmotic symptoms suggestive of diabetes 
mellitus. He was found to be volume depleted with a 
blood pressure 70/40 mmHg. Investigations revealed mild 
azotemia, which resolved on rehydration, and an elevated 
random blood sugar of 24 mmol/L.
A diagnosis of NODAT was made and he was started 
initially on insulin because of intercurrent illness, and 
was later switched to gliclazide (diamicron) 80 mg daily 
with good glycemic control. His last fasting blood glucose 
was 6.2 mmol/L.
Case 2
A 36-year-old school teacher who had kidney transplantation 
done in our center. His primary renal disease was chronic 
glomerulonephritis. He had no history of cigarette smoking 
or alcohol ingestion. He had a family history of hypertension 
(father) and diabetes mellitus (mother) but no family history 
of kidney disease. His height was 1.67 m, weight 68 kg, 
and BMI 24 kg/m2. His serology for HBsAg, HCV-Ab, 
and retroviral screen were all negative. His donor was his 
26-year-old brother. At induction, he was given intravenous 
methylprednisolone 500 mg and this was repeated on the 
second and third day. Oral Cyclosporine was also given 
at induction. Maintenance immunosuppression included 
cyclosporine, azathioprine, and prednisolone 20 mg daily 
from Day 3, which was tapered from the third month. 
He maintained a good allograft function and by the fifth 
day, his creatinine had normalized to 84 µmol/L. He was 
discharged by the eleventh day post-op with a creatinine 
of 92 µmol/L and blood pressure of 120/70 mmHg. He 
remained stable on follow-up and by the third month post 
transplant he presented with a 3 days’ history of excessive 
thirst and water intake and excessive micturition. No 
history of fever, dysuria, or loin pain. Urgent random blood 
sugar was 20 mmol/L, fasting blood sugar 20.1 mmol/L, 
and lipid profile was normal. Diagnosis of NODAT was 
made and he was counseled on the nature of the disease, 
dietary advice was given, and he was started on metformin 
and later glibenclamide. His blood sugar was controlled 
successfully and allograft function remained excellent. 
Eight months later, he was brought to the emergency room 
by his relatives with 1-day history of sudden collapse and 
loss of consciousness. Urgent brain CT revealed extensive 
intracerebral hemorrhage. He was managed as a case of 
hemorrhagic cerebrovascular disease, but he expired within 
24 hours of admission.
Case 3
A 25-year-old civil servant who had living related kidney 
transplant in India one year prior to presentation. Her 
primary renal disease was unknown. She was not a 
known diabetic. Her donor was her brother. Immediate 
post- transplant course was unremarkable. HLA typing was 
not reported. Her immunosuppressant protocol include 
prednisolone 7.5 mg daily, Tacrolimus 4 mg twice daily, and 
mycophenolate mofetil 500 mg twice daily.
She was noted to have developed progressively rising blood 
sugar on routine follow-up without significant osmotic 
symptoms. There was no significant improvement on dietary 
modification and oral hypoglycemics. She was switched to 
mixtard insulin with good glycemic control at a dose of 
24 units in the morning and 10 units in the evening. She 
maintained good graft function on outpatient follow-up with 
serum creatinine about 80 µmol/L. She was admitted with 
features of urosepsis and acute allograft dysfunction. Her 
creatinine on admission was 425 µmol/L. Full blood count 
revealed anemia with a hemoglobin of 7.5 g/dL, leukocytosis 
with white cell count of 27 × 109/L, and differential showing 
neutrophils of 89%. Platelets were normal. Her random 
blood sugar on admission was 9.1 mmol/L. Renal allograft 
ultrasound revealed mildly enlarged kidneys with bipolar 
diameter of 13 cm, increased echogenicity, but preserved 
cortico–medullary differentiation.
She was treated with intravenous ceftriaxone and a 
3-day course of methylprednisolone, and tacrolimus was 
temporarily withheld. She was continued on mixtard insulin 
with blood sugar monitoring.
Urine culture yielded Enterococcus fecalis sensitive 
to levofloxacin and ciprofloxacin. She improved and 
was discharged on oral levofloxacin and maintenance 
immunosuppressants with improved allograft function, 
to continue follow-up on outpatient basis. Her serum 
creatinine at discharge was 177 µmol/L.
Discussion
Renal transplantation is becoming increasingly available 
in Nigeria after the first successful kidney transplant in a 
private hospital in 2000.[4]
Two years after that, two government hospitals started renal 
transplant programs.[5,6] With the increase in overall life 
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expectancy of post-renal transplant recipients, the likelihood 
of long-term transplant-related complications now present 
a major challenge to the quality of life of these patients.[1] 
Studies have shown that cardiovascular diseases, infections, 
and metabolic conditions like diabetes mellitus constitute the 
main long-term complications of post-renal transplant drug 
management.[1,2] The factors implicated in the development of 
new-onset diabetes after renal transplant include older age of 
the patient, post-prandial hyperglycemia, immunosuppressive 
drugs (steroids, calcineurin inhibitors), and mammalian 
target of rapamycin inhibitors, obesity, presence of hepatitis 
C viral infection, and unhealthy lifestyle.[3,7] Although the 
relationship of type 2 diabetes and hepatitis C virus (HCV) 
in the general population has been described,[8] an association 
between NODAT and HCV has been found in both kidney 
and liver transplant patients.[7,8] Although pathophysiological 
mechanism of HCV-induced NODAT is not quite clear, 
HCV induced autoimmune or direct b-cell damage, 
development of insulin resistance, hemochromatosis, and 
fibrosis are recognized as factors responsible for the NODAT 
development.[9,10] The traditional risk factors for developing 
diabetes mellitus as in the general population, if present in 
renal transplant patients, can also significantly increase the 
chances of diabetes mellitus.
All the three cases described in this report demonstrated 
significant use of immunomodulating agents like prednisolone, 
which could partly explain the new-onset transplant-
associated diabetes mellitus. The diagnosis of diabetes mellitus 
in these patients met the current WHO criteria.[11] Only one 
of the patients had a significant family history of diabetes 
mellitus, which probably increased the risk of NODAT. The 
exact mechanism of diabetes in renal transplant patients is 
not known. Controversies exist as to the relative contribution 
of therapy in the development of diabetes in renal transplant 
patients. One recent study that compared the risk of 
developing NODAT in persons receiving tacrolimus versus 
those on cyclosporine observed increased tendency towards 
diabetes among those on tacrolimus.[12] If the observations 
from this study are true, it may be possible that the use of 
tacrolimus in addition to the presence of hepatitis C viral 
infection in Case 1 predisposed the patient to developing 
diabetes mellitus. However, it is widely acceptable that use 
of drugs like prednisolone and methylprednisolone, especially 
over prolonged periods, substantially increase the risk of renal 
transplant-related diabetes mellitus.[13]
With advances in renal transplantation and increase in 
availability of transplant in our setting, it is anticipated 
that many patients would develop metabolic problems, 
especially diabetes. A comprehensive evaluation of these 
patients for possible risk factors for the development of 
diabetes must be undertaken before the transplant and 
periodically during the course of post-transplant follow-
up and therapy. Screening for abnormalities of glucose 
metabolism should be routine in patients before and 
after renal transplantation; immunosuppression should 
be modified according to the risk of new-onset diabetes 
mellitus and the likelihood of acute rejection. In this way, 
the devastating effects of diabetes would be minimized in 
our renal transplant patients.
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